Skip to content

Investigation of blood kinetics at the time of ingestion of coating processed glucosamine hydrochloride

Investigation of blood kinetics at the time of ingestion of coating processed glucosamine hydrochloride - Investigation of blood kinetics at the time of ingestion of coating processed glucosamine hydrochloride

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025863
Enrollment
6
Registered
2017-01-26
Start date
2017-01-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy male

Interventions

Intake of coating processed glucosamine hydrochloride Intake of no coating processed glucosamine hydrochloride

Sponsors

TTC Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Healthy males from 20 to 64 years of age

Exclusion criteria

Exclusion criteria: (1) Subjects routinely taking medicine or health food that may affect the evaluation of the study (2) Subjects who has under treatment or a history of serious disease(e.g., diabetes, liver disease, kidney disease, or heart disease) (3) Subjects having possibilities for emerging allergy related to the current study (4) Subjects who are under medication or having a history of serious diseases for which medication was required (5) Subjects taking warfarin (product name: Warfarin, Warin, Alephrine, Warfarin K etc) for cerebral infarction or heart disease etc., those who need to take warfarin during the research period (6) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study (7) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire (8) Subjects who are judged as unsuitable for the current study based on the results of clinical and physical preliminary examination (9) Subjects judged as unsuitable for the study by the investigator for other reasons

Design outcomes

Primary

MeasureTime frame
Area under the curve of plasma glucosamine levels

Secondary

MeasureTime frame
maximum plasma glucosamine levels, glucosamine concentration at each time point

Countries

Japan

Contacts

Public ContactShinsuke Tsuji

TTC Co., Ltd Clinical Research Planning Department

s.tsuji@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026